The COVID-19 Pandemic and the Ethical Duties of the Neurologist
Neurol 95:167-172, Rubin, M.A.,et al, 2020
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke
Ann Neurol 88:946-955, Triantafyllou, S.,et al, 2020
Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy
NEJM 383:2547-2556, Pennell, P.G.,et al, 2020
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019
Hemophagocytic Lymphohistiocytosis Associated with the Use of Lamotrigine
Neurol 92:e2401-e2405, Kim, T.,et al, 2019
Recommendations for the Establishment of Stroke Systems of Care
Stroke 50:e1-e24, Adeoye, O.,et al, 2019
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age with Epilepsy
JAMA Neurol 76:783-790, Kim, H.,et al, 2019
Risk of 23 Specific Malformations Associated with Prenatal Exposure to 10 Antiepileptic Drugs
Neurol 93:e167-e180, Blotiere, P.O.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Declining Malformation Rates with Changed Antiepileptic Drug Prescribing, An Observational Study
Neurol 93:e831-e840, Tomson,T.,et al, 2019
Acute Treatment of Migraine in Children and Adolescents
Neurol 93:487-499, Oskoui, M.,et al, 2019
Pharmacologic Treatment for Pediatric Migraine Prevention
Neurol 93:500-509, Oskoui, M.,et al, 2019
Dupuytren, Ledderhose, and Peyronie Diseases after Primidone Use for Essential Tremor
Neurologist 24:150-151, Felipe, L.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019
Recurrent Epistaxis in an Adolescent
BMJ 367:I5393, McLaren, O. & Ronan, N., 2019
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus
NEJM 381:2103-2113,2171, Kapur, J.,et al, 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
GGC Repeat Expansion of NOTCH2NLC in Adult Patients with Leukoencephalopathy
Ann Neurol 86:962-968,809, Okubo, M.,et al, 2019
Automated ASPECTS in Acute Ischmeic Stroke: A Comparative Analysis with CT Perfusion
AJNR 40:2033-2038, Sundaram, V.K.,et al, 2019
Long-Term Treatment Effect in Cerebrotendinous Xanthomatosis Depends on Age at Treatment Start
Neurol 92:e83-e95, Stelten, B.M.L.,et al, 2019
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA 32:175-187, Brown, J.W.L.,et al, 2019
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Hereditary Spastic Paraplegia:From Diagnosis to Emerging Therapeutic Approaches
Lancet Neurol 18:1136-1146, Shribman,S.,et al, 2019
Ischemic Stroke and Internal Carotid Artery Web
Stroke 50:e31-e34, Mc Grory, B.,et al, 2019
Cholesterol Lowering and Prevention of Stroke
Stroke 50:537-541, Hackam, D.G. & Hegele, R.A., 2019
Simultaneous CMV and Listeria Infection Following Alemtuzumab Treatment for Multiple Sclerosis
Neurol 92:296-298, Pappolla, A.,et al, 2019
Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs with Risk for Attention-Deficit/Hyperactivity Disorder in Offspring
JAMA Netw Open 2:e186606, Christensen, J.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Paraoxysmal Tonic Upgaze in Children, Three Case Reports and a Review of the Literature
Pediatr Emer Care 35:e67-e69, Kartal,A., 2019
Management of Acute Retinal Ischemia
Ophthalmol 125:1597-1607, Viousse, V.,et al, 2018
MOG Encephalomyelitis: International Recommendations on Diagnosis and Antibody Testing
J Neuroinflammation 15:134, Jarius, S.et al, 2018
Dual Antiplatelet Therapy with Aspirin and Clopidogrel for Acute High Risk Transient Ischaemic Attack and Minor Ischaemic Stroke: A Clinical Practice Guideline
BMJ 363:k5130, Prasad, K.,et al, 2018
Evidence-Based Management of Patent Foramen Ovale in Patients with Ischemic Stroke
JAMA Neurol 75:147-148, Kamel, H., 2018
Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People with Antiphospholipid Syndrome
Stroke 49:e41-e42, Bala, M.M.,et al, 2018
Stroke Prevention in the Very Elderly
Stroke 49:796-802, Lindley, R.I., 2018
Abdominal Migraine
BMJ 360;k179, Angus-Leppan, H.,et al, 2018
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Antiepileptic Drug Treatment After An Unprovoked First Seizure
Neurol 91:e1429-e1439,684, Bao, E.L.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
Misdiagnosis of Multiple Sclerosis
Neurol 92:15-16, Brownlee, W.J., 2018